Dr Vinay Prasad resigned from the FDA after less than three months amid controversy over the Generapor and pressure of Sarepta Therapeutics of the White House. He plans to return to California to spend more time with his family. The FDA regulator Dr. Vinay Prasad resigned. (X) Dr. Vinay Prasad, a top regulator at the US Food and Drug Administration, resigned in less than three months in the track after a controversy over the handling of Sarepta Therapeutics Inc. gene therapy. “Dr Prasad did not want to be a distraction for the great work of the FDA in the Trump administration and decided to return to California and spend more time with his family,” a report from CNN cited a US Department of Health and Human Services spokesman. Who is Vinay Prasad? In May, Prasad, a hematologist and oncologist, was appointed head of the FDA’s Center for Biological Evaluation and Research, which gave him authority over vaccines and biological medicine. He was also appointed as the FDA’s chief medical and scientific officer. Similar to several Trump Administration Health appointments, Prasad was a vocal critic of the government’s response and vaccine policy during the Covid-19 pandemic. Vinay Prasad’s resignation the report, citing people who are aware of the development, said Prasad resigned amid the pressure of the White House. In addition, Laura Loomer, a right -wing activist who is known to have close ties with Donald Trump, has continuously criticized Prasad. She publicly criticized him for days on her website and social media and called him a ‘progressive left -wing saboteur’ which undermines ‘President Trump’s FDA’. Loomer exclaimed Prasad’s previous social media posts and podcast episodes, where she claimed to have supported liberal politicians and expressed “contempt” for Trump. The FDA commissioner, dr. Marty Makary, however, defended Prasad a few days ago. In an interview with politico, Makary said Prasad is an ‘impeccable scientist … one of the greatest scientific thoughts of our generation.’ “We thank him for his service and the many important reforms he could achieve in his time at FDA,” the HHS spokesman said. Sarepta Gene Therapy -Controversy Prasad took on his role with the FDA after years of outspoken criticism of certain approvals by the agency. Strikingly, he condemned the approval of Sarepta’s Duchenne -muscle dystrophy, Elevidys, and claimed that there was insufficient evidence to demonstrate that it was effectively delayed or reversed, or reversed on this rare and deadly genetic condition. This month, the FDA asked Sarepta to stop the drug delays of the drug after a death of a young patient in Brazil. Just a day before Prasad’s departure, the agency unexpectedly reversed its decision and allowed Sarepta to continue the shipping for certain patients. Prasad faced criticism from former officials and vaccine experts after May’s internal memos showed that he rejected FDA scientists to two new Covid-19 vaccine versions. The then director of the Coder criticized the broad use of these vaccines; Eventually, the FDA approved them for parent and immune promotion individuals, but did not recommend them to younger Americans without underlying health conditions.
Who is Vinay Prasad? The top regulator of the US FDA leaves agency after controversy over Sarepta Gene Therapy | Today news
